Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (114)
ARTG (99)
Australian Public Assessment Report (AusPAR) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (11)
2015 (8)
2014 (8)
2013 (14)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1994 (1)
1993 (3)
1991 (2)

Results for "[search-keyword]"

Search

Sponsor content

225 result(s) found, displaying 91 to 100

NYXOID naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial (309381)

18 September 2018

ARTG

Australian Register of Therapeutic Goods (ARTG) information for NYXOID naloxone hydrochloride dihydrate 2.2 mg/actuation nasal spray vial.
DICODIN dihydrocodeine tartrate 90mg modified release tablet bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DICODIN dihydrocodeine tartrate 90mg modified release tablet blister pack Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DICODIN dihydrocodeine tartrate 120mg modified release tablet bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DICODIN dihydrocodeine tartrate 120mg modified release tablet blister pack Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
YTRACIS yttrium [90Y] chloride 1.850GBQ/ml radiopharmaceutical precursor solution vial Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
PALLADONE XL hydromorphone hydrochloride 12mg capsule bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
PALLADONE XL hydromorphone hydrochloride 16mg capsule bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
PALLADONE XL hydromorphone hydrochloride 24mg capsule bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
PALLADONE XL hydromorphone hydrochloride 32mg capsule bottle Section 30(1)(c) of the Act

14 April 2020

Cancellation by sponsor

Requested by Mundipharma Pty Ltd

Pages

First page
Previous page
…
Page 6
Page 7
Page 8
Page 9
Current page 10
Page 11
Page 12
Page 13
Page 14
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.